Scherer/Marquest
This article was originally published in The Gray Sheet
Executive Summary
Complete $4.5 mil. "sale-and-leaseback" financing arrangement under which Scherer obtains rights to Marquest's ABG blood gas analysis product line; Scherer is licensing the rights back to Marquest ("The Gray Sheet" April 26, p. 16). Under the previously announced financing agreement, the firms also collaborated to complete an exchange offer for approximately 90% of Marquest's $12.7 mil. in defaulted Swiss bonds. Approximately 4,000 shares of Scherer 5% convertible preferred stock, $2.7 mil. of Marquest six-year 8% notes, and Marquest warrants for 1.4 mil. common shares will be issued in exchange for the tendered bonds. In conjunction with the transaction, Scherer received warrants for 6.6 mil. shares of Marquest common stock, exercisable at 75 cents per share. "At Scherer's option, either cash or Scherer common stock can be used in exercising the warrants," according to a joint June 17 press release.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.